Walvax Biotechnology Co.,Ltd.(300142.SZ)
Profile
Registered Capital:
150.00(RMB MLN)
Employees：
581
Email：
IR@walvax.com.cn
WebSite：
http://www.walvax.com.cn
Tel：
0871-8312779
Fax：
0871-8312779
Walvax Biotechnology Co., Ltd. is principally engaged in the research, development, production and distribution of human vaccine products. The Company primarily provides haemophilus influenzae B vaccines, which are applied in the prevention of meningitis, pneumonia, septicemia, cellulitis, arthritis and pharyngitis caused by Hib, as well as group A and group C meningococcal polysaccharide vaccines, which are applied in the prevention of diseases caused by group A and group C meningococcal polysaccharide, such as cerebrospinal meningitis and septicemia. The Company distributes its products primarily in domestic market.
Reports
- In-depth Report of Walvax Biotechnology Co.,Ltd.(300142.SZ)
- Credit Report of Walvax Biotechnology Co.,Ltd.(300142.SZ)
- Financial Report of Walvax Biotechnology Co.,Ltd.(300142.SZ)
- China Blood Product Industry Report, 2015-20182015/4/30
- China Human Vaccine Industry Report, 2015-20182015/3/27
- Global and China Monoclonal Antibody Industry Report, 2014-20192014/10/20
- China Human Vaccine Industry Report, 2014-20172014/8/29
- China Blood Product Industry Report, 2014-20172014/7/10
- Global and China Monoclonal Antibody Industry Report, 2013-20172013/12/23
- China Human Vaccine Industry Report, 2012-20152013/8/22
- China Blood Product Industry Report, 2012-20152013/7/4
Walvax Biotechnology produces Hib Vaccine (a vaccine for viral hepatitis) and A, C Meningococcal Polysaccharide Conjugate Vaccine, which made up 65.26% and 13.59% of its 2009 revenues, with annual production capacity of eight million and five million vaccines, respectively. The company's clients are mostly disease control centers and medicine dealers.